ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

FX-322 in Adults With Stable Sensorineural Hearing Loss

ClinicalTrials.gov ID: NCT04120116

Public ClinicalTrials.gov record NCT04120116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Study identification

NCT ID
NCT04120116
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Frequency Therapeutics
Industry
Enrollment
95 participants

Conditions and interventions

Interventions

  • FX-322 (Four Doses) Drug
  • FX-322 (One Dose) Drug
  • FX-322 (Two Doses) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 3, 2019
Primary completion
Oct 5, 2020
Completion
Dec 16, 2020
Last update posted
Apr 26, 2023

2019 – 2020

United States locations

U.S. sites
16
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Clinical Trial Site Fresno California 93720
Clinical Trial Site Torrance California 90503
Clinical Trial Site Colorado Springs Colorado 80909
Clinical Trial Site Boca Raton Florida 33487
Clinical Trial Site Sarasota Florida 34239
Clinical Trial Site Tampa Florida 33612
Clinical Trial Site Louisville Kentucky 40207
Clinical Trial Site Omaha Nebraska 68118
Clinical Trial Site Amherst New York 14226
Clinical Trial Site Matthews North Carolina 28105
Clinical Trial Site Winston-Salem North Carolina 27103
Clinical Trial Site Orangeburg South Carolina 29118
Clinical Trial Site Austin Texas 78705
Clinical Trial Site San Antonio Texas 78240
Clinical Trial Site San Antonio Texas 78258
Clinical Trial Site Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04120116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 26, 2023 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04120116 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →